Ipilimumab

Generic Name: Ipilimumab

Brand Names: Yervoy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 477202-00-9

Unique Ingredient Identifier: 6T8C155666

Background: Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication: Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer

- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab

Associated Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)

Associated Therapies: First Line Chemotherapy

Clinical Trials

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

First Posted Date: 2020-10-19

Last Posted Date: 2023-10-03

Lead Sponsor: Fondazione per la Medicina Personalizzata

Target Recruit Count: 400

Registration Number: NCT04591431

Locations: 🇮🇹
I.R.S.T. Srl Irccs, Meldola, Italy
🇮🇹
Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
🇮🇹
I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy

and more 34 locations

Nivolumab+Ipilimumab+RT in MSS mCRC

Phase 2

Active, not recruiting

Conditions: Metastatic Microsatellite Stable Colorectal Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Radiation: Radiation Therapy

First Posted Date: 2020-10-05

Last Posted Date: 2022-09-08

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 32

Registration Number: NCT04575922

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Phase 2

Recruiting

Conditions: Melanoma Stage III
Melanoma Stage IV
Inoperable Disease

Interventions: Drug: Interleukin-2
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2020-09-24

Last Posted Date: 2024-10-31

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 29

Registration Number: NCT04562129

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Phase 2

Active, not recruiting

Conditions: Metastatic Soft-tissue Sarcoma

Interventions: Drug: Cabozantinib
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2020-09-16

Last Posted Date: 2024-06-10

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 105

Registration Number: NCT04551430

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Abramson Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
University of Colorado, Aurora, Colorado, United States

and more 1 locations

Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Phase 1

Completed

Conditions: Clear-Cell Renal Cell Carcinoma

Interventions: Drug: Sitravatinib
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2020-08-19

Last Posted Date: 2024-06-05

Lead Sponsor: Mirati Therapeutics Inc.

Target Recruit Count: 22

Registration Number: NCT04518046

Locations: 🇺🇸
MD Anderson, Houston, Texas, United States

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

Phase 1

Active, not recruiting

Conditions: Advanced Melanoma
Renal Cell Carcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: APX005M

First Posted Date: 2020-07-31

Last Posted Date: 2024-06-21

Lead Sponsor: Yale University

Target Recruit Count: 26

Registration Number: NCT04495257

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma

Phase 2

Active, not recruiting

Conditions: Undifferentiated Pleomorphic Sarcoma
Myxofibrosarcoma

Interventions: Biological: Envafolimab
Drug: Ipilimumab

First Posted Date: 2020-07-21

Last Posted Date: 2024-05-17

Lead Sponsor: Tracon Pharmaceuticals Inc.

Target Recruit Count: 207

Registration Number: NCT04480502

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

and more 27 locations